In a research report issued Monday, Maxim analyst Jason McCarthy reiterated a Buy rating on Galena Biopharma Inc (NASDAQ:GALE) with a price target of …
Galena Biopharma Inc (NASDAQ:GALE) announced data from the Company’s GALE-301 Phase 1/2a clinical trial was presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in …
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today …
Shares of Galena are being materially undervalued, analyst Vernon Bernardino says
Maxim analyst Jason McCarthy provides insight on shares of Galena Biopharma Inc (NASDAQ:GALE) after the company posted second-quarter results. While McCarthy reiterates a Buy …
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, reported …
FBR analyst Vernon Bernardino was out today with a mix report on shares of Galena Biopharma Inc (NASDAQ:GALE), reiterating an Outperform rating while slashing the …
Analyst Jason McCarthy of Maxim Group maintained a Buy rating for Galena Biopharma Inc (NASDAQ:GALE), but decreased his price target to $2, marking a 340% increase …
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major medical needs, today announced …
